SCHEMBL6675846

SCHEMBL6675846

CC(C)(C)C(=O)C[Si](C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 1/20 0.31
HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13141790 0.76
SCHEMBL755487 0.67 KMT2A (0.39) KMT2ATSHRHSD11B1
SCHEMBL93393 0.67 KMT2A (0.39) KMT2ARAB9ATSHRHSD11B1
SCHEMBL4837194 0.67 KMT2A (0.39) KMT2ARAB9ATSHRHSD11B1
SCHEMBL7698150 0.67 KMT2A (0.31) KMT2A
SCHEMBL9019859 0.65 DGAT1 (0.34) SMN1; SMN2
SCHEMBL9566006 0.65 KMT2A (0.37) KMT2ARAB9ATSHRHSD11B1
SCHEMBL15788938 0.65 KMT2A (0.37) KMT2ARAB9ATSHRHSD11B1
SCHEMBL7141290 0.65 KMT2A (0.37) KMT2ARAB9ATSHRHSD11B1
SCHEMBL21405194 0.65 KMT2A (0.37) KMT2ARAB9ATSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365541-A1 INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-11-16 US disclosed
US-20040215030-A1 Precursors for metal containing films VERSUM MATERIALS US, LLC 2004-10-28 US disclosed
EP-1471568-A1 Precursors for metal containing films AIR PRODUCTS AND CHEMICALS, INC. (US) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365541-A1 INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF EZH2, BMI1, EZH1 KMT2A 17/4885RAB9A 2688/4885SMN1; SMN2 903/4885
US-20040215030-A1 Precursors for metal containing films TBL3, TBL2, TNNI3 KMT2A 802/4885RAB9A 2003/4885SMN1; SMN2 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.